Charles Schwab Investment Management Inc. raised its stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM – Free Report) by 309.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,093 shares of the company’s stock after acquiring an additional 52,965 shares during the period. Charles Schwab Investment Management Inc. owned 0.24% of Eliem Therapeutics worth $357,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in ELYM. Rhumbline Advisers acquired a new position in Eliem Therapeutics during the 2nd quarter valued at approximately $59,000. SG Americas Securities LLC bought a new stake in Eliem Therapeutics in the third quarter valued at $60,000. Chicago Partners Investment Group LLC acquired a new position in shares of Eliem Therapeutics during the third quarter valued at $81,000. Dimensional Fund Advisors LP acquired a new position in shares of Eliem Therapeutics during the second quarter valued at $89,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Eliem Therapeutics during the second quarter worth about $134,000. 69.76% of the stock is owned by institutional investors.
Eliem Therapeutics Stock Down 13.5 %
Shares of NASDAQ:ELYM opened at $2.03 on Friday. The company’s 50-day moving average price is $3.67 and its 200 day moving average price is $5.92. The company has a market cap of $60.25 million, a PE ratio of -3.82 and a beta of -0.39. Eliem Therapeutics, Inc. has a fifty-two week low of $2.35 and a fifty-two week high of $11.55.
About Eliem Therapeutics
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Read More
- Five stocks we like better than Eliem Therapeutics
- Investing In Automotive Stocks
- Micron Stock Under $100: Seize the AI-Driven Upside
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- What Do S&P 500 Stocks Tell Investors About the Market?
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Want to see what other hedge funds are holding ELYM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eliem Therapeutics, Inc. (NASDAQ:ELYM – Free Report).
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
